Rivaroxaban (Xarelto; Bayer/Janssen) has gained an additional indication, this time for venous thromboembolism (VTE) prophylaxis in acutely ill hospitalized patients at increased risk for ...

PARIS, France—To head off the risk of device-related thrombus after left atrial appendage (LAA) occlusion, a reduced dose of rivaroxaban may be a viable alternative to dual antiplatelet therapy (DAPT) ...

Expert Rev Cardiovasc Ther. 2009;7(6):569-576. Rivaroxaban may have the potential to offer clinicians the option of a fixed-dose, unmonitored, once-daily, oral anticoagulant for VTE prevention after ...

(HealthDay News) — Rivaroxaban is associated with reduced risk of recurrent events among patients with venous thromboembolism in equipoise for continued anticoagulation, according to a study published ...

Venous thromboembolism (VTE) following joint replacement surgery represents an economic as well as a clinical burden; however, the risk of thromboembolic events is greatly reduced by appropriate ...

Global pharma major Lupin Limited (Lupin) announced that it has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application for rivaroxaban ...

The Appraisal Committee considered evidence submitted by the manufacturer of rivaroxaban and a review of this submission by the Evidence Review Group (ERG). The manufacturer's submission compared ...

The phase 3 GALILEO trial has been terminated early after a preliminary analysis showed that rivaroxaban (Xarelto; Bayer/Janssen) was associated with an increase in all-cause death, thromboembolic ...

Please provide your email address to receive an email when new articles are posted on . Patients undergoing total hip or knee arthroplasty are at increased risk of venous thromboembolism (VTE). The ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio PARIS — In the AFIRE trial, rivaroxaban ...